Regulatory Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara Pharmaceutical Business ReviewLanglara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM).Read full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaceutical Business Review Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM). Read full story Post navigation Previous: ‘Seismic shift’ as obesity overtakes cancer for R&D returnsNext: Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
